Valeant Pharmaceuticals (VRX) needs a ‘fix it” third party to come in and stop the bleeding. Moreover, the current management team is stuck in ‘deer in headlights mode’, and needs to start taking proactive steps to resolve the overhang that is weighing down investor confidence on the street.